Results 261 to 270 of about 206,426 (300)

Antibodies to beta(2)-glycoprotein I in ischemic stroke.

Cerebrovascular diseases (Basel, Switzerland), 2000
Antibodies to beta(2)-glycoprotein (beta(2)-GPI) have been associated with recurrent thrombotic events in patients with systemic lupus erythematosus. The present study investigated the prevalence of antibodies to beta(2)-GPI in an unselected group of patients with ischemic stroke.
Fiallo P, Tomasina C, Clapasson A, CARDO, PASQUALE PAOLO   +3 more
openaire   +2 more sources

The interaction of beta 2 glycoprotein-I and heparin and its effect on beta 2 glycoprotein-I antiphospholipid antibody cofactor function in plasma.

Thrombosis and haemostasis, 1995
beta 2 glycoprotein-I (beta 2GPI), a cofactor for antiphospholipid antibody (aPA) binding, binds to many anionic macromolecules including heparin. The nature of this interaction with heparin is not well understood and its effect on the purported biological functions of beta 2GPI is unknown.
T, McNally, S E, Cotterell, I J, Mackie, D A, Isenberg, S J, Machin   +4 more
openaire   +1 more source

Anti-beta(2)-glycoprotein I antibody-mediated inhibition of activated protein C requires binding of beta(2)-glycoprotein I to phospholipids.

Thrombosis and haemostasis, 2003
To clarify the role(s) of anti-beta(2) GPI antibodies on thrombosis in anti-phospholipid antibody syndromes (APS), the effect of IgG from three patients on activated protein C (APC) was investigated using phospholipid vesicles and purified proteins. Two of the total IgG inhibited APC activity in the presence of beta(2)GPI, whereas the third IgG did not.
Tomonori, Izumi, Mary L, Pound, Zuowei, Su, G Michael, Iverson, Thomas L, Ortel   +4 more
openaire   +1 more source

Beta2-Glycoprotein I

Lupus, 1994
D A, Kandiah, S A, Krilis
openaire   +2 more sources

Beta-2-glycoprotein-I IgA antibodies predict coronary plaque progression in rheumatoid arthritis.

Seminars in Arthritis & Rheumatism, 2020
G. Karpouzas, S. Ormseth, E. Hernandez, Viet L Bui, M. Budoff   +4 more
semanticscholar   +1 more source

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial

Nature Medicine, 2022
, Darin K Edwards, Rolando Pajon
exaly  

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Nature Communications, 2020
Timothy P Sheahan, Sarah R Leist, Alexandra Schäfer   +2 more
exaly  

Evaluation of three fully automated immunoassay systems for detection of IgA anti‐beta 2‐glycoprotein I antibodies

International Journal of Laboratory Hematology, 2016
D. Pérez, J. A. Martínez-Flores, M. Serrano, D. Lora, E. Paz-Artal, J. Morales, A. Serrano   +6 more
semanticscholar   +1 more source

New Tests to Detect Antiphospholipid Antibodies: Anti-Domain I Beta-2-Glycoprotein-I Antibodies

Current Rheumatology Reports, 2014
C. Chighizola, M. Gerosa, P. Meroni
semanticscholar   +1 more source

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Lancet, The, 2020
Kwok-Cheung Lung, Tom Wai-Hin Chung, Hoi-Ping Shum   +2 more
exaly